ストックスクリーナーアプリを入手
4.65
0.21%
-0.010
アフターアワーズ：
4.65
前日終値:
$4.66
開ける：
$4.73
24時間の取引高:
2.00M
Relative Volume:
0.64
時価総額：
$1.27B
収益：
$8.10M
当期純損益:
$-92.72M
株価収益率:
-13.02
EPS:
-0.3571
ネットキャッシュフロー:
$-82.52M
1週間 パフォーマンス:
+5.44%
1か月 パフォーマンス:
-4.32%
6か月 パフォーマンス:
+59.79%
1年 パフォーマンス:
+190.62%
1日の値動き範囲:
$4.47
$4.74
1週間の範囲:
$4.365
$4.74
52週間の値動き範囲:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
名前
Taysha Gene Therapies Inc
セクター
電話
(214) 612-0000
住所
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.65 | 1.28B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Raymond James | Strong Buy |
| 2025-07-11 | 開始されました | BofA Securities | Buy |
| 2024-06-27 | 開始されました | BMO Capital Markets | Outperform |
| 2024-04-09 | 開始されました | Piper Sandler | Overweight |
| 2023-02-01 | ダウングレード | Jefferies | Buy → Hold |
| 2023-01-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | ダウングレード | Goldman | Buy → Neutral |
| 2022-03-09 | 開始されました | Robert W. Baird | Outperform |
| 2022-03-01 | 開始されました | Wells Fargo | Overweight |
| 2022-02-18 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-16 | 開始されました | Guggenheim | Buy |
| 2021-07-16 | 開始されました | Needham | Buy |
| 2021-06-24 | 開始されました | Truist | Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-06-09 | 開始されました | Wedbush | Outperform |
| 2021-06-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 再開されました | Jefferies | Buy |
| 2021-02-24 | 開始されました | William Blair | Outperform |
| 2021-01-05 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-19 | 開始されました | Goldman | Buy |
| 2020-10-19 | 開始されました | Jefferies | Buy |
| 2020-10-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Taysha Gene Therapies Inc (TSHA) 最新ニュース
Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Tybourne Capital Management HK Ltd. - MarketBeat
Is Taysha Gene Therapies Inc undervalued by DCF analysisJuly 2025 Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
Retail Trends: What is the next catalyst for Taysha Gene Therapies IncPortfolio Gains Summary & High Accuracy Buy Signal Tips - baoquankhu1.vn
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies (TSHA) Awards Restricted Stock Units to Ne - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Did Rett Trial Milestones Just Shift Taysha Gene Therapies' (TSHA) Gene Therapy Approval Path Narrative? - Yahoo Finance
Taysha Gene Therapies, Inc. (TSHA) gains Wells Fargo’s support on Rett syndrome program progress - MSN
Taysha’s REVEAL Trial Progress Puts Rett Gene Therapy And Valuation In Focus - Sahm
Cell And Gene Therapy Enters ‘Disciplined Growth Cycle’ As Commercial Momentum Builds - Citeline News & Insights
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress - Finviz
Institution Moves: Does Taysha Gene Therapies Inc have strong fundamentals2025 Retail Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
Taysha Gene Therapies, Inc. $TSHA Shares Sold by SG Americas Securities LLC - MarketBeat
Activity Recap: How cyclical is Taysha Gene Therapies Incs revenue streamWeekly Stock Report & Precise Trade Entry Recommendations - baoquankhu1.vn
Pivotal Trial for Taysha's Rett Syndrome Gene Therapy TSHA-102 Doses First Patient - CGTLive®
Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans - NeurologyLive
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
10 Best Strong Buy Stocks to Invest In Under $5 - Insider Monkey
Here’s What Analysts Are Saying About Taysha Gene Therapies (TSHA) - Insider Monkey
Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA) - Finviz
Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells $649,747.75 in Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells 41,312 Shares of Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 26,918 Shares of Stock - MarketBeat
Kamran Alam Sells 78,968 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Kamran Alam Sells 23,849 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.2%What's Next? - MarketBeat
Taysha Gene Therapies Targets Genetic Neurological Conditions - Kalkine Media
Taysha Gene Therapies commences underwritten public offering - MSN
Dip Buying: How liquid is Taysha Gene Therapies Inc stock2025 Support & Resistance & Entry Point Strategy Guides - baoquankhu1.vn
Trading Recap: Can PBYI generate free cash flowJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
VIX Spike: Is Taysha Gene Therapies Inc stock good for income investors2025 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of Stock - MarketBeat
Nagendran sells Taysha gene therapies (TSHA) stock for $942k By Investing.com - Investing.com Canada
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects - Insider Monkey
10 Best Penny Stocks to Buy for 2026 - Insider Monkey
Buybacks Report: What is KIDSs TAM Total Addressable MarketIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.3%Should You Sell? - MarketBeat
Taysha Gene Therapies Advances TSHA-102 Program - MSN
Taysha Gene Therapies (TSHA) Stock Analysis: Unveiling a 114% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Is Taysha Gene Therapies Inc. stock a buy on dipsMarket Volume Report & High Conviction Investment Ideas - ulpravda.ru
Is Taysha Gene Therapies Inc. stock attractive for long term wealth buildingJuly 2025 Earnings & Detailed Earnings Play Alerts - ulpravda.ru
Is Taysha Gene Therapies Inc. stock vulnerable to regulatory risks2025 Technical Patterns & Fast Exit and Entry Strategy Plans - Улправда
Is Taysha Gene Therapies Inc. stock a bargain at current levelsJuly 2025 Summary & Verified Chart Pattern Signals - Улправда
Can Taysha Gene Therapies Inc. stock beat analyst upgradesMarket Performance Report & High Conviction Buy Zone Alerts - ulpravda.ru
Can Taysha Gene Therapies Inc. stock rebound after recent weaknessJuly 2025 PreEarnings & Smart Money Movement Alerts - Улправда
Should I hold or sell Taysha Gene Therapies Inc. stock in 2025July 2025 Action & Reliable Entry Point Alerts - Улправда
Will Taysha Gene Therapies Inc. stock benefit from green energy trendsJuly 2025 Recap & Low Risk High Win Rate Picks - ulpravda.ru
Pivotal trial of Rett gene therapy TSHA-102 now underway, and recruiting - Rett Syndrome News
Taysha doses first patient in pivotal Rett syndrome gene therapy trial - Investing.com Nigeria
Taysha Gene Therapies Inc (TSHA) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):